Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
Key result
Angiotensin AT1 receptor blockers provide an alternative blockade of the renin-angiotensin system that may confer additional cardiovascular protection and are generally better tolerated than ACE inhibitors.
Population
Patients with or at risk for cardiovascular disease, including those with hypertension, diabetes, heart…
Comparison
Angiotensin AT1 receptor blockers (ARBs) vs Angiotensin-converting enzyme (ACE) inhibitors
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
ARBs may be preferred in ACE-intolerant patients; leaves open need for head-to-head outcome trials.
Structured PICO
P
Population
Patients with or at risk for cardiovascular disease, including those with hypertension, diabetes, heart failure post-myocardial infarction, left ventricular dysfunction, and renal disease
I
Intervention
Angiotensin AT1 receptor blockers (ARBs)
C
Comparator
Angiotensin-converting enzyme (ACE) inhibitors
ARBs offer an effective and better-tolerated alternative to ACE inhibitors for cardiovascular protection, with growing evidence supporting their combination in certain circumstances.
Cite This Study
Ruilope et al. (2005) conducted a review in Cardiovascular disease. Angiotensin AT1 receptor blockers (ARBs) vs. ACE inhibitors was evaluated. Angiotensin AT1 receptor blockers provide an alternative blockade of the renin-angiotensin system that may confer additional cardiovascular protection and are generally better tolerated than ACE inhibitors.